Literature DB >> 30143352

Association between loss of heterozygosity of chromosome 16q and survival in Wilms' tumor: A meta-analysis.

Qingting Bu1, Hairong He2, Di Fan3, Jun Lyu4, Zhenyu Pan5, Haisheng You6.   

Abstract

BACKGROUND: Wilms' tumor (WT) is the most common pediatric renal tumor. Despite its high survival rate, the potential prognostic factors should further be studied to reduce the intensity of the treatment. A few studies have found LOH of 16q is associated with worse survival in patients with WT, but it is still contradictory. This study aimed to performed a meta-analysis to clarify this.
METHODS: Databases including the Wanfang, PubMed, Chinese National Knowledge Infrastructure, Embase, and Cochrane Library databases were searched July 2018. The meta-analysis was done using Stata (version 14.0). Publication bias was evaluated by funnel plots, Begg's test, and Egger's test. The trim-and-fill method was applied if significant publication bias existed. Sensitivity analysis was performed to evaluate the stability of the results.
RESULTS: This meta-analysis identified 9 cohort studies encompassing 3266 cases. The pooled relative risk when comparing LOH of 16q groups with control groups was 2.22 [95% confidence interval (CI) = 1.64-3.00, P < 0.001], and the pooled hazard ratio was 1.92 (95%CI = 1.32-2.80, P = 0.001). The results were stable after correcting for publication bias and performing a leave-one-out sensitivity analysis.
CONCLUSIONS: This meta-analysis indicated that LOH of 16q was significantly associated with worse survival in WT. Further studies need to identify this conclusion because the overall quality of the included studies is not high, investigate the impact of LOH of 16q on the survival of WT patients in different subgroups and identify better treatments for WT patients with LOH of 16q in order to lengthen their survival.
Copyright © 2018. Published by Elsevier GmbH.

Entities:  

Keywords:  LOH of 16q; Meta-analysis; Survival; Wilms’ tumor

Mesh:

Year:  2018        PMID: 30143352     DOI: 10.1016/j.prp.2018.08.010

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

1.  Development and validation of a nomogram for predicting cancer-specific survival in patients with Wilms' tumor.

Authors:  Zhenyu Pan; Haisheng You; Qingting Bu; Xiaojie Feng; Fanfan Zhao; Yuanjie Li; Jun Lyu
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

2.  Loss of Heterozygosity at Chromosome 16q Is a Negative Prognostic Factor in Korean Pediatric Patients with Favorable Histology Wilms Tumor: A Report of the Korean Pediatric Hematology Oncology Group (K-PHOG).

Authors:  Jun Eun Park; O Kyu Noh; Yonghee Lee; Hyoung Soo Choi; Jung Woo Han; Seung Min Hahn; Chuhl Joo Lyu; Ji Won Lee; Keon Hee Yoo; Hong Hoe Koo; Seon-Yong Jeong; Ki Woong Sung
Journal:  Cancer Res Treat       Date:  2019-09-10       Impact factor: 4.679

3.  RNA-Sequencing, Connectivity Mapping, and Molecular Docking to Investigate Ligand-Protein Binding for Potential Drug Candidates for the Treatment of Wilms Tumor.

Authors:  Jia-Yuan Luo; Shi-Bai Yan; Gang Chen; Peng Chen; Song-Wu Liang; Qiong-Qian Xu; Jin-Han Gu; Zhi-Guang Huang; Li-Ting Qin; Hui-Ping Lu; Wei-Jia Mo; Yi-Ge Luo; Jia-Bo Chen
Journal:  Med Sci Monit       Date:  2020-03-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.